Prior Authorization May Reduce Access, Uptake Of HIV PrEP

Infectious Disease Advisor (12/19, Barowski) reports, “Prior authorization requirements may be directly associated with reduced access and uptake of HIV pre-exposure prophylaxis (PrEP) in areas with high rates of HIV diagnoses, according to study results published in JAMA Network Open.” In the study, researchers “evaluated specialty tiering for 2 PrEP regimens: emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) and FTC/tenofovir alafenamide (TAF). The primary outcomes were annual variation (2018-2020) in qualified health plan coverage (QHP) and prior authorization requirements for FTC/TDF and FTC/TAF.”